Neutrophil cytosol factor 4 (p40phox) (p40phox)

Neutrophil cytosol factor 4 (NCF4), commonly known as p40phox, is a critical cytosolic regulatory subunit of the phagocyte NADPH oxidase (NOX2) complex (UniProt Q15080). It plays a pivotal role in the innate immune response by facilitating the production of reactive oxygen species (ROS), specifically superoxide anions, which are essential for the destruction of engulfed pathogens during phagocytosis (PubMed 16102041). Structurally, p40phox contains a phox homology (PX) domain that specifically binds to phosphatidylinositol 3-phosphate (PtdIns(3)P) on phagosomal membranes, thereby directing the assembly and activation of the NOX2 complex at the site of infection (PubMed 12887891). Mutations in the NCF4 gene are associated with a rare form of autosomal recessive chronic granulomatous disease (CGD), characterized by impaired ROS production and increased susceptibility to infections, as well as inflammatory conditions like Crohn's disease and rheumatoid arthritis (PubMed 30166340, GeneCards NCF4). While no drugs currently target p40phox exclusively, it is a key component of the NOX2 complex, which is a major therapeutic target for inflammatory and autoimmune disorders (PubMed 26160156). Research into small-molecule inhibitors of the NOX2 complex, such as GSK2795039 and various p47phox-p22phox interaction inhibitors, aims to modulate ROS production to treat chronic inflammation without compromising host defense (PubMed 26160156, PubMed 32003593). Additionally, anti-TNF therapies have been observed to downregulate NCF4 expression in conditions like ankylosing spondylitis, suggesting its role as a downstream mediator of inflammatory signaling (PubMed 37711844).

Other names

NCF4NCF-4SH3 and PX domain-containing protein 4Neutrophil NADPH oxidase factor 4SH3PXD4CGD3p40-phox

Therapeutic strategies targeting the NOX2 complex, including p40phox, involve the use of small-molecule inhibitors that disrupt the assembly of cytosolic regulatory subunits (p40phox, p47phox, p67phox) with the membrane-bound catalytic core (gp91phox/p22phox) or directly inhibit the enzyme's catalytic activity (PubMed 26160156, PubMed 32003593). Some inhibitors specifically target the protein-protein interactions between subunits, such as the p47phox-p22phox or p67phox-Rac interfaces, thereby preventing the formation of a functional oxidase complex (PubMed 22134915).